Hims & Hers Health company profile
Company profile
Hims & Hers Health has 2,442 employees and is headquartered in San Francisco, United States.
Based in San Francisco, California, Hims & Hers Health, Inc. has existed since 2017 as a consumer health and wellness platform that links customers with licensed healthcare professionals. Prescription and non-prescription products are sold through its websites, mobile application, retail partners and stores, alongside medical consultations and laboratory testing. Under the Hims & Hers brand, it offers over-the-counter drugs, devices, cosmetics and supplements for skincare, sexual health, hair care and general wellness, plus treatments for chronic conditions in hormone health, weight loss, dermatology and mental health. Customers are served in the United States, the United Kingdom, Canada, Germany, Ireland, France, Spain, Australia and elsewhere.
In the fiscal year ended December 31, 2025, revenue reached $2.3 billion, up 59.0% from the previous year, and net income was $128.4 million. The United States generated 94.3% of revenue. The company, formerly Hims, Inc. until its name change in January 2021, employs 2,442 people and is headquartered in San Francisco.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Headquarters
- 2269 Chestnut Street, 94123, San Francisco
- Employees
- 2,442
- Chief executive
- Andrew Dudum
- Founded
- 2017
- Fiscal year
- January - December
- Listing
- HIMS · NYSE
- Currency
- USD
- ISIN
- US4330001060
- Website
- hims.com
Hims & Hers Health and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Hims & Hers HealthHIMS | United States | $3.42B | 2,442 | -6.4% | — |
| Neurocrine BiosciencesNBIX | United States | $15.24B | 2,500 | 26.6% | 22.3 |
| ViatrisVTRS | United States | $22.5B | 30,000 | 11.5% | — |
| United TherapeuticsUTHR | United States | $23.63B | 1,400 | 39.4% | 20.9 |
| ZoetisZTS | United States | $32.14B | 14,500 | 37.9% | 13.5 |
| Teva Pharmaceutical IndustriesTEVA | United States | $45.77B | 31,173 | 19.8% | 91.2 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
